http://cancerres.aacrjournals.org/cg...tract/68/3/826
Note the interesting conclusion:
"This study provides a rationale
to combine HER inhibitors with tamoxifen in clinical studies,
even in tumors that do not initially overexpress EGFR/HER2."
Hopeful